Scientific publications

Peroxisome proliferator-activated receptor alpha and hypertensive heart disease

Goikoetxea M.J., Beaumont J., Díez J.
Area of Cardiovascular Pathophysiology, Centre for Applied Medical Research, University Clinic, School of Medicine, University of Navarra, Pamplona, Spain.

Magazine: Drugs

Date: Feb 1, 2004


Peroxisome proliferator-activated receptor alpha (PPARalpha) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. It is expressed by cardiomyocytes and regulates gene expression of key proteins involved in myocardial lipid and energy metabolism. Accordingly, the activitity of PPARalpha is an important determinant of cardiomyocyte lipid homeostasis and ATP production.

Currently, animal and human data suggest that deactivation of PPARalpha may contribute substantially to phenotypic changes that accompany cardiac growth in conditions of pressure overload, and the hypothesis emerges that a compromised PPARalpha activity may participate in the transition from compensated left ventricular hypertrophy to heart failure in hypertensive heart disease.

The availability of PPARalpha activators (e.g. fibric acid derivates and statins) must stimulate investigation into the potential cardioprotective actions of these compounds beyond their hypolipidaemic effects and via restoration of PPARalpha activity in the hypertrophied and failing heart.

CITATION  Drugs. 2004;64 Suppl 2:9-18

you maybe interested


The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra